AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23237127 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC) alone
Number of subjects: 180
Study 23237127 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (supportive therapy)
Number of subjects: 180
Study 23237127 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation manipulation intervention
Number of subjects: 180
Study 21605672 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (28,000 IU/week)
Number of subjects: 160
Study 21605672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 19104825 — intervention group
Group type: EXPERIMENTAL
Intervention: White test (WT)
Number of subjects: 137
Study 19104825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bile leakage test)
Number of subjects: 137
Study 18390492 — intervention group
Group type: EXPERIMENTAL
Intervention: HR intervention group
Number of subjects: 508
Study 18390492 — intervention group
Group type: COMPARATOR
Intervention: HR control group
Number of subjects: 508
Study 18390492 — intervention group
Group type: COMPARATOR
Intervention: LR control group
Number of subjects: 508
Study 15516290 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/h F transdermal patches (N = 142)
Number of subjects: 546
Study 15516290 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/h F transdermal patches (N = 184)
Number of subjects: 546
Study 15516290 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg/h F transdermal patches (N = 85)
Number of subjects: 546
Study 15516290 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg/h F transdermal patches (N = 135)
Number of subjects: 546
Study 11303191 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 617
Study 11303191 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling regarding sexually transmitted disease
Number of subjects: 617
Study 9722255 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic dexamethasone for 3 d followed by nebulized budesonide for 18 d
Number of subjects: 60
Study 9722255 — intervention group
Group type: COMPARATOR
Intervention: Systemic and inhaled saline
Number of subjects: 60
Study 7979565 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin supplementation including 0.8 mg folic acid
Number of subjects: 5502
Study 7979565 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin supplementation
Number of subjects: 5502
Study 3058630 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of steroids (32 mg of oral methylprednisolone, approximately 2 hours before CM challenge)
Number of subjects: 6763
Study 3058630 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of steroids (32 mg approximately 12 hours and 2 hours before CM challenge)
Number of subjects: 6763
Study 3058630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6763
Study 4939601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrimidazine (Naxogin)
Number of subjects: 57
Study 4939601 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (Flagyl)
Number of subjects: 57
Study 30316671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 30316671 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (Cystectomy)
Number of subjects: 0
Study 30316671 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 0
Study 30316671 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic treatment
Number of subjects: 0
Study 30316671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonotherapy
Number of subjects: 0
Study 30316671 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal carcinomas
Number of subjects: 0
Study 29401355 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy (AAT)
Number of subjects: 0
Study 27401657 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-implantation of a preloaded capsular tension ring (CTR) and aberration-free monofocal intraocular lens (IOL)
Number of subjects: 52
Study 27401657 — intervention group
Group type: COMPARATOR
Intervention: Monofocal intraocular lens (IOL) only
Number of subjects: 52
Study 25209072 — intervention group
Group type: EXPERIMENTAL
Intervention: B'More Healthy Communities for Kids (BHCK) intervention
Number of subjects: 0
Study 22124795 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg Cu/d (supplemented group, SG)
Number of subjects: 0
Study 22124795 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group, PG)
Number of subjects: 0
Study 19561530 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 818
Study 19561530 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine scheduled daily
Number of subjects: 818
Study 19561530 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 818
Study 17957730 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS with strong but comfortable non-painful stimulation
Number of subjects: 66
Study 17957730 — intervention group
Group type: COMPARATOR
Intervention: TENS with sensory threshold stimulation
Number of subjects: 66
Study 15922284 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 53
Study 15922284 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 53
Study 12192167 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HepB combination vaccine
Number of subjects: 0
Study 12192167 — intervention group
Group type: COMPARATOR
Intervention: Monovalent HepB vaccine
Number of subjects: 0
Study 9655370 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA group (7 subjects) - 6 g DHA/d for 90 days after a basal diet for 30 days
Number of subjects: 11
Study 9655370 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 subjects) - stabilization or basal diet throughout the study
Number of subjects: 11
Study 8075614 — intervention group
Group type: COMPARATOR
Intervention: Pulmicort
Number of subjects: 47
Study 8075614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2592587 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine (100 mg) administered after an overnight fast
Number of subjects: 24
Study 2592587 — intervention group
Group type: COMPARATOR
Intervention: Velnacrine (100 mg) administered 15 minutes after a standard breakfast
Number of subjects: 24
Study 5002114 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 50
Study 5002114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 50
Study 5002114 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 50
Study 5002114 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise-induced asthma)
Number of subjects: 50
Study 31418414 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model based on age, Child‐Pugh classification, and fibrinogen
Number of subjects: 262
Study 31418414 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of the prediction model
Number of subjects: 262
Study 29247110 — intervention group
Group type: EXPERIMENTAL
Intervention: eDCT
Number of subjects: 1354
Study 29247110 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 1354
Study 26323681 — intervention group
Group type: EXPERIMENTAL
Intervention: 88% phenol
Number of subjects: 49
Study 26323681 — intervention group
Group type: COMPARATOR
Intervention: 10% sodium hydroxide
Number of subjects: 49
Study 25041495 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 67
Study 25041495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 67
Study 22936319 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized therapy group (I-125 seeds implantation combined with chemotherapy and Chinese medicine)
Number of subjects: 90
Study 22936319 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus CM-treated group
Number of subjects: 90
Study 22936319 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-treated group
Number of subjects: 90
Study 18926641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 55
Study 18926641 — intervention group
Group type: COMPARATOR
Intervention: Monoamine reuptake inhibitors
Number of subjects: 55
Study 18926641 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 55
Study 17632217 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine, 400 mg/d at bedtime
Number of subjects: 61
Study 17632217 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 61
Study 17632217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 14767152 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal cognitive-behavioral therapy (CBT)
Number of subjects: 42
Study 11396366 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide, epirubicin, fluorouracil)
Number of subjects: 0
Study 11396366 — intervention group
Group type: EXPERIMENTAL
Intervention: AC‐>T (doxorubicin, cyclophosphamide, followed by paclitaxel)
Number of subjects: 0
Study 11396366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense, dose-intense EC‐>T (epirubicin, cyclophosphamide, followed by paclitaxel)
Number of subjects: 0
Study 11396366 — intervention group
Group type: COMPARATOR
Intervention: Previous regimens (CEF, FEC 100, CAF, AC‐>T)
Number of subjects: 0
Study 9432099 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (1 training task once a week for 5 weeks)
Number of subjects: 30
Study 9432099 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (2 training tasks per week for 2 weeks, then 3 tasks per week for 3 weeks)
Number of subjects: 30
Study 9432099 — intervention group
Group type: COMPARATOR
Intervention: Group C (control group, no additional eccentric exercise)
Number of subjects: 30
Study 8234907 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg t.i.d.)
Number of subjects: 10
Study 8234907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2826098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal of whole-meal (diabetic diet)
Number of subjects: 19
Study 2826098 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw wheat whole-meal preparation
Number of subjects: 19
Study 2826098 — intervention group
Group type: COMPARATOR
Intervention: Heated wheat and corn whole-meal preparations
Number of subjects: 19
Study 2826098 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw corn (oat) variant
Number of subjects: 19
Study 31915255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (oral, 10 mg)
Number of subjects: 0
Study 31915255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30268096 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMS (Gait Enhancing Mechatronic System)
Number of subjects: 15
Study 30268096 — intervention group
Group type: COMPARATOR
Intervention: NoGEMS (free ascending stairs)
Number of subjects: 15
Study 28348720 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy carried out by a psychologist
Number of subjects: 170
Study 28348720 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 170
Study 28348720 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 170
Study 25619445 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient referral alone
Number of subjects: 0
Study 25619445 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider referral
Number of subjects: 0
Study 25619445 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract referral
Number of subjects: 0
Study 23903476 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.03% budesonide rinse
Number of subjects: 50
Study 23903476 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.01% dexamethasone rinse
Number of subjects: 50
Study 21098871 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 3 months
Number of subjects: 92
Study 21098871 — intervention group
Group type: COMPARATOR
Intervention: Control group (statin-free patients)
Number of subjects: 92
Study 21098871 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 92
Study 18795985 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 3 weeks
Number of subjects: 52
Study 18795985 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 6 weeks
Number of subjects: 52
Study 18795985 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP for 3 weeks followed by therapeutic CPAP for 3 weeks
Number of subjects: 52
Study 18795985 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 52
Study 17018819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 302
Study 17018819 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 302
Study 14725659 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 12
Study 14725659 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 12
Study 10885554 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 0
Study 10885554 — intervention group
Group type: COMPARATOR
Intervention: Conventional open operations
Number of subjects: 0
Study 10885554 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised studies
Number of subjects: 0
Study 9478066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 788
Study 9478066 — intervention group
Group type: EXPERIMENTAL
Intervention: Paralysis
Number of subjects: 788
Study 9478066 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight reduction over 10 kg vs ideal weight
Number of subjects: 788
Study 9478066 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint deformation
Number of subjects: 788
Study 9478066 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment
Number of subjects: 788
Study 8334888 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic combined oral contraceptive
Number of subjects: 1088
Study 8334888 — intervention group
Group type: COMPARATOR
Intervention: Low-dose monophasic combined oral contraceptive
Number of subjects: 1088
Study 3090012 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at sea level
Number of subjects: 8
Study 3090012 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 100% O2 at altitude
Number of subjects: 8
Study 3090012 — intervention group
Group type: EXPERIMENTAL
Intervention: O2 consumption exceeding 2.7 1/min at sea level
Number of subjects: 8
Study 3090012 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexes of VA/Q dispersion
Number of subjects: 8
Study 28103746 — intervention group
Group type: EXPERIMENTAL
Intervention: Human sender feedback
Number of subjects: 0
Study 28103746 — intervention group
Group type: EXPERIMENTAL
Intervention: Human emotional feedback
Number of subjects: 0
Study 28103746 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback processing
Number of subjects: 0
Study 27305596 — intervention group
Group type: EXPERIMENTAL
Intervention: RF tissue reduction under local anesthesia with epinephrine
Number of subjects: 120
Study 27305596 — intervention group
Group type: COMPARATOR
Intervention: RF tissue reduction under local anesthesia without epinephrine
Number of subjects: 120
Study 27305596 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group 1 and group 2
Number of subjects: 120
Study 24621680 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg twice daily
Number of subjects: 1006
Study 24621680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1006
Study 24621680 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 1006
Study 22430564 — intervention group
Group type: EXPERIMENTAL
Intervention: Image comparison method
Number of subjects: 126
Study 22430564 — intervention group
Group type: COMPARATOR
Intervention: Adjacent prosthesis
Number of subjects: 126
Study 20642691 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO-beta (30,000 UI each) administered before surgery and at 12 h, 7 days, and 14 days posttransplantation.
Number of subjects: 104
Study 20642691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPO-beta treatment).
Number of subjects: 104
Study 20642691 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO-beta group.
Number of subjects: 104
Study 20642691 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 104
Study 20642691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups.
Number of subjects: 104
Study 17301056 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention (home-based physical exercise, dietary instructions, management aspects) for 15 months
Number of subjects: 1135
Study 17301056 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1135
Study 15918388 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. remifentanil PCA (loading dose: 45 microg, maintenance dose: 1 microg min(‐1), bolus dose: 15 microg, lockout interval: 10 min)
Number of subjects: 69
Study 15918388 — intervention group
Group type: COMPARATOR
Intervention: i.v. morphine PCA (loading dose: 5 mg, maintenance dose: 0.3 mg h(‐1), bolus dose: 1 mg, lockout interval: 15 min)
Number of subjects: 69
Study 11448655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg + sulfonylurea
Number of subjects: 560
Study 11448655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg + sulfonylurea
Number of subjects: 560
Study 11448655 — intervention group
Group type: COMPARATOR
Intervention: Placebo + sulfonylurea
Number of subjects: 560
Study 9738729 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% sucrose diet
Number of subjects: 9
Study 9738729 — intervention group
Group type: COMPARATOR
Intervention: 2% sucrose diet
Number of subjects: 9
Study 7913852 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0
Study 7913852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2691494 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery (CS) with radiotherapy (RT)
Number of subjects: 0
Study 2691494 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 0
Study 7995695 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene membrane
Number of subjects: 38
Study 7995695 — intervention group
Group type: COMPARATOR
Intervention: Control (no membrane)
Number of subjects: 38
Study 465179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine plus usual treatment (rehydration, refeeding, furazolidone)
Number of subjects: 32
Study 465179 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (rehydration, refeeding, furazolidone)
Number of subjects: 32
Study 31009433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-set (CLUS, n = 11)
Number of subjects: 21
Study 31009433 — intervention group
Group type: COMPARATOR
Intervention: Traditional-set (TRAD, n = 10)
Number of subjects: 21
Study 31093318 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 42
Study 31093318 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 42
Study 31093318 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 42
Study 28809658 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Functional (Cog-Fun) occupational therapy intervention
Number of subjects: 107
Study 28809658 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 107
Study 26437500 — intervention group
Group type: EXPERIMENTAL
Intervention: Refurbished resin composite restorations
Number of subjects: 26
Study 26437500 — intervention group
Group type: COMPARATOR
Intervention: Untreated (negative control) restorations
Number of subjects: 26
Study 24521630 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 28
Study 24521630 — intervention group
Group type: COMPARATOR
Intervention: Gluten free diet, calcium and cholecalciferol (Control)
Number of subjects: 28
Study 21247825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-focused health management program
Number of subjects: 130
Study 19725969 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching antipsychotics
Number of subjects: 0
Study 19725969 — intervention group
Group type: COMPARATOR
Intervention: Initial antipsychotic therapy
Number of subjects: 0
Study 17563126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg plus paracetamol 500 mg
Number of subjects: 10
Study 17563126 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg
Number of subjects: 10
Study 15068395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 760
Study 15068395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study 15068395 — intervention group
Group type: EXPERIMENTAL
Intervention: E298 allele
Number of subjects: 760
Study 15068395 — intervention group
Group type: EXPERIMENTAL
Intervention: 4a allele
Number of subjects: 760
Study 15068395 — intervention group
Group type: EXPERIMENTAL
Intervention: D/D298 homozygotes
Number of subjects: 760
Study 15068395 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐786T allele
Number of subjects: 760
Study 11403726 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (20 mg)
Number of subjects: 16
Study 11403726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9951580 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy including doxorubicin and/or cyclophosphamide
Number of subjects: 0
Study 9951580 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without doxorubicin and/or cyclophosphamide
Number of subjects: 0
Study 8091240 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent cisplatin
Number of subjects: 0
Study 8091240 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based multiagent chemotherapy
Number of subjects: 0